Lv5
904 积分 2024-02-22 加入
CDI-DTI: A Strong Cross-Domain Interpretable Drug-Target Interaction Prediction Framework Based on Multi-Strategy Fusion
15小时前
待确认
Synthetic lethality: targeting the SMARCA2 bromodomain for degradation in SMARCA4 deficient tumors-a review of patent literature from 2019-June 2023
4个月前
已完结
PD-1 and PD-1 ligands: from discovery to clinical application
5个月前
已完结
Discovery of FHD-286, a First-in-Class, Orally Bioavailable, Allosteric Dual Inhibitor of the Brahma Homologue (BRM) and Brahma-Related Gene 1 (BRG1) ATPase Activity for the Treatment of SWItch/Sucrose Non-Fermentable (SWI/SNF) Dependent Cancers
5个月前
已完结
SMARCA4 and SMARCA2 co-deficiency: An uncommon molecular signature defining a subset of rare, aggressive and undifferentiated malignancies associated with defective chromatin remodeling
5个月前
已完结
皖公网安备34019202002308
